Potentially practice-changing data was presented at 2018 ASH Annual Meeting and Exposition (December 1–4, 2018; CA, USA), read our round-up to discover the key studies. Highlights include the CASSINI and MAIA trial data,
Browsing: Taxonomy > Clinical trials
Thomas Seufferlein discusses diagnostic and treatment options for pancreatic cancer, as well as his thoughts on recent advancements, emerging treatments and trials, such as the TRYbeCA1 study.
A new oral drug designed to improve efficacy of radiotherapy has been shown to be effective and safe as an adjunctive treatment for hard-to-treat cancers.
Authors discuss the results of this observational real-world study and how sequencing tyrosine kinase inhibitors can extend chemotherapy-free treatment time.
SOLO-1 is the first, double-blind, randomized, prospective Phase III trial to evaluate front-line olaparib maintenance therapy after platinum-based chemotherapy in newly diagnosed advanced ovarian cancer with BRCA mutation.
Two-year maintenance therapy with olaparib improves PFS in newly diagnosed patients with advanced ovarian cancer with a BRCA1 or 2 mutation.
A major trial has demonstrated that fulvestrant–palbociclib combination therapy may prolong survival and delay the need for chemotherapy in women with advanced breast cancer.
In this round up we provide you with the biggest headlines and highlights from the IASLC World Conference on Lung Cancer (WCLC) the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
A Phase III trial involving the combination of immunotherapy and chemotherapy has seen significantly improved overall survival and progression-free survival in extensive-stage small-cell lung cancer patients.